---
title: Retrospective Comparative Outcomes of Gamma and InterTAN Nail for Unstable Intertrochanteric Hip Fractures
nct_id: NCT07282236
overall_status: COMPLETED
sponsor: Fundación Universidad Católica de Valencia San Vicente Mártir
study_type: OBSERVATIONAL
primary_condition: Unstable Throchanteric Hip Fractures
countries: Spain
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07282236.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07282236"
ct_last_update_post_date: 2026-01-13
last_seen_at: "2026-05-12T06:33:24.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Retrospective Comparative Outcomes of Gamma and InterTAN Nail for Unstable Intertrochanteric Hip Fractures

**Official Title:** Quality of Reduction, Position of the Lag Screw and Mechanical Complications in Unstable Interthrochanteric Hip Fractures. A Comparison Between Gamma and InterTAN Nail.

**NCT ID:** [NCT07282236](https://clinicaltrials.gov/study/NCT07282236)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 686
- **Lead Sponsor:** Fundación Universidad Católica de Valencia San Vicente Mártir
- **Conditions:** Unstable Throchanteric Hip Fractures, Pertrochanteric Fracture of Femur
- **Start Date:** 2025-12-13
- **Completion Date:** 2026-01-12
- **CT.gov Last Update:** 2026-01-13

## Brief Summary

Objective: compare outcomes of unstable intertrochanteric hip fractures treated with two commercially available implants. Design: retrospective observational cohort of 288 treated with a Gamma® nail and 398 with an InterTAN® nail. Patients were operated between 1997 and 2010. Primary outcomes: satisfactory reduction, optimal cephalic screw placement, and to evaluate the incidence of mechanical complications; secondary measures included the tip-apex distance (TAD), hematocrit (Hto) and hemoglobin (Hb) drop, transfusion requirement and volume, hospital length of stay and the time to first ambulation.

## Detailed Description

Rationale: to evaluate whether outcomes differ between two commonly used cephalomedullary nails for unstable intertrochanteric hip fractures in routine practice.

Setting: double-centre, single-city retrospective cohort with consecutive patients treated by the same surgeon-Gamma2® at the Hospital Clínico Universitario (1997-2002; n=288) and InterTAN® at Vithas Hospitals (2002-2010; n=398). Cohorts: defined by the implant used in usual care; adults ≥65 years with unstable AO/OTA A2-A3 patterns were included; key exclusions were stable patterns, pathologic fractures, subtrochanteric extension, poor radiographs, and \<6-month follow-up. Planned analyses: between-group comparisons of reoperation and implant-related complications (primary focus), plus perioperative and functional parameters, using χ²/t-tests as appropriate adjusting for age, sex, ASA class, AO/OTA pattern, reduction quality, and screw position metrics (e.g., TAD); results reported as effect sizes with 95% CIs, with sensitivity analyses by fracture pattern and reduction quality

## Eligibility

- **Minimum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Unstable trochanteric fractures confirmed radiographically according to OTA (Orthopedic Trauma Association), treated with Gamma or InterTAN nail,
* available follow-up for ≥ 6 months

Exclusion Criteria:

* Pathological fractures
* Polytrauma precluding standard treatment/follow-up
* Missing key variables/outcomes
```

## Arms

- **Gamma Nail Group** — The Gamma Nail Group consists of patients diagnosed with unstable trochanteric fractures who underwent surgical management using a Gamma cephalomedullary nail. This intervention involves internal fixation with a short or long intramedullary device designed to provide stable biomechanical support for unstable peritrochanteric fracture patterns. Patients in this group received the Gamma nail as the primary method of fracture stabilization, with the goal of achieving early mobilization, maintaining fracture alignment, and reducing the risk of mechanical complication.
- **InterTAN Nail Group** — The InterTAN Nail Group includes patients with unstable trochanteric fractures who were treated surgically using an InterTAN cephalomedullary nail. This intervention consists of internal fixation with a dual integrated screw intramedullary device designed to enhance rotational and axial stability in unstable peritrochanteric fracture patterns. Patients in this group received the InterTAN nail as the primary method of fracture stabilization, aiming to improve construct rigidity, facilitate early mobilization, and support optimal fracture healing.

## Interventions

- **Fracture fixation with cephalomedullary nails** (DEVICE) — No differences with the routine surgery for trochanteric fractures

## Primary Outcomes

- **Implant-related complications** _(time frame: 6 months)_ — Incidence of device-related adverse events (e.g., cut-out, varus collapse).

## Secondary Outcomes

- **Quality of fracture reduction** _(time frame: Immediately postoperative (within 24 hours))_
- **Cephalic screw placement** _(time frame: Immediately postoperative (within 24 hours))_

## Locations (1)

- School of Medicine and Health Sciences, Valencia Catholic University, Valencia, VALÈNCIA, Spain

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.school of medicine and health sciences, valencia catholic university|valencia|valència|spain` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07282236.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07282236*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*